Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTX-04
- Development stage
- Preclinical
- Lead developer
- Next Innovative Therapeutics
01
Overview
NTX-04 is an investigational drug candidate being developed by Next Innovative Therapeutics (Nintx) for the treatment of irritable bowel syndrome (IBS). It is part of Nintx's pipeline of therapies designed to target biological pathways directly and indirectly through gut microbiome modulation, leveraging plant-based natural products. NTX-04 is currently in the discovery stage of development.
Beyond the preview
Go deeper on NTX-04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTX-04.